LL-37, human 是一種由37個氨基酸殘基組成的兩親性組織蛋白酶衍生的抗菌肽，具有廣泛的抗菌活性。它有助于保護角膜免受感染，對于傷口愈合有著良好的促進作用，同時對多種革蘭氏陽性和革蘭氏陰性病原體具有抗菌和抗生物膜活性。

LL-37, human is a 37-residue, amphipathic, cathelicidin-derivedantimicrobial peptide, which exhibits a broad spectrum ofantimicrobial activity. LL-37, human could help protect thecornea from infection and modulates wound healing.

LL-37是一種具有血管生成活性的抗菌肽。它對應于人組織蛋白酶抗菌蛋白hCAP18/LL-37的C末端序列（134-170），并通過蛋白水解過程從hCAP18/LL-37細胞外釋放。hCAP18/LL-37是先天免疫系統(tǒng)的效應器，在白細胞和上皮細胞中表達，與炎癥和損傷相關上調?？梢宰C明hCAP18/LL-37在一系列乳腺癌中的過表達。LL-37被認為部分通過甲酰肽受體樣1（FPRL1）刺激上皮細胞增殖，因為用百日咳毒素阻斷受體會使LL-37的增殖作用降低約50%。

LL-37 is an antimicrobial peptide with angiogenic activity. Itcorresponds to the C-terminal sequence (134-170) of the humancathelicidin antimicrobial protein hCAP18/LL-37 and isextracellularly released from hCAP18/LL-37 by proteolyticprocessing. hCAP18/LL-37 is an effector of the innate immune systemand is expressed in leukocytes and epithelial cells where it isupregulated in association with inflammation and injury. Anoverexpression of hCAP18/LL-37 in a series of breast carcinomascould be demonstrated. LL-37 has been suggested to stimulateepithelial cell proliferation partially through formyl peptidereceptor-like 1 (FPRL1) since blocking the receptor with pertussistoxin decreased the proliferative effect of LL-37 by approximately50 %.

該產品由合肥肽庫生物科技有限公司生產合成，合肥肽庫生物專注科研多肽定制合成，以技術引領多肽科研

編號:125937中文名稱:兩親性組織蛋白酶衍生的抗菌肽：LL-37 (Cathelicidin)英文名:LL-37 (Cathelicidin)英文同義詞:LL37CAS號:154947-66-7單字母:H2N-LLGDFFRKSKEKIGKEFKRIVOH三字母:H2N-Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-OH氨基酸個數(shù):37分子式:C205H340N60O53平均分子量:4493.26分子量:4490.58等電點(PI):11.7pH=7.0時的凈電荷數(shù):6.98平均親水性:0.67647058823529疏水性值:-0.72